Vir Biotechnology, Inc. VIR License and collaboration revenue — Upfront payments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept vir:CollaborativeArrangementAmountOfUpfrontPaymentAndNearTermMilestone.
The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053549
Concurrently with the closing of the Astellas Collaboration Agreement, the Company also closed the Stock Purchase Agreement with Astellas (the Astellas SPA, together with the Astellas Collaboration Agreement, the Astellas Agreements), under which Astellas purchased 7,239,382 shares of the Company’s common stock for an aggregate purchase price of approximately $75.0 million. The fair value of these common stock was $75.7 million, based on the market price of $10.46 per share on the closing day. As a result, $0.7 million of the $240.0 million upfront payment under the Astellas Collaboration Agreement was attributed to the common stock issuance for accounting purposes, resulting in a residual upfront payment of $239.3 million. The Astellas SPA includes standstill, voting and lockup provisions, with customary exceptions, that expire one year after the date of the closing of the Astellas SPA. One year after the closing of the Astellas SPA, Astellas will have, under certain circumstances, a customary right to require the Company to register the resale of the shares purchased pursuant to the Astellas SPA.
Item 1. Financial Statements (unaudited)
FAQ
- What is Vir Biotechnology, Inc.'s license and collaboration revenue — upfront payments?
- Vir Biotechnology, Inc. (VIR) reported license and collaboration revenue — upfront payments of $239.3M in Q2 2026.
- What does license and collaboration revenue — upfront payments mean?
- This metric represents the non-refundable initial payments received from strategic partners upon the execution of a license or collaboration agreement. These payments are typically recognized as revenue when the intellectual property license is granted or when specific performance obligations are satisfied under the contract terms. It serves as a key indicator of the company's ability to monetize its research platforms and pipeline assets through external partnerships.
Ask your AI about Vir Biotechnology, Inc.'s license and collaboration revenue — upfront payments.
Connect your AI assistant and compare it to peers, right in your chat.
